6 studies found for:    INCB039110
Show Display Options
Rank Status Study
1 Completed A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of INCB039110 in Subjects With Active Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Interventions: Drug: INCB039110;   Drug: INCB039110 Placebo
2 Active, not recruiting An Open Label Study of INCB039110 Administered Orally in Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Post Polycythemia Vera Fibrosis;   Post Essential Thrombocythemia Myelofibrosis
Intervention: Drug: INCB039110
3 Completed A Study of Escalating Doses of INCB039110 Administered Orally in Patients With Plaque Psoriasis
Condition: Chronic Plaque Psoriasis
Interventions: Drug: INCB039110;   Drug: Placebo
4 Recruiting Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: INCB039110;   Drug: Placebo;   Drug: docetaxel
5 Recruiting Safety Study of INCB039110 in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Conditions: Metastatic Cancer;   Metastatic Pancreatic Cancer
Interventions: Drug: INCB039110;   Drug: Gemcitabine;   Drug: nab-paclitaxel;   Drug: filgrastim
6 Recruiting Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies
Condition: B-cell Malignancies
Interventions: Drug: INCB040093;   Drug: INCB040093 + INCB039110

Indicates status has not been verified in more than two years